Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine()

BACKGROUND: Multiple sclerosis (MS) patients receive immunomodulatory treatments which can influence their ability to maintain vaccine specific serological response overtime. MS patients treated with cladribine tablets developed a positive serology response following two doses of mRNA COVID-19 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Livnat, Rechtman, Ariel, Shifrin, Alla, Rozenberg, Ayal, Afanasiev, Svetlana, Zveik, Omri, Haham, Nitzan, Levin, Neta, Vaknin-Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088160/
https://www.ncbi.nlm.nih.gov/pubmed/35667316
http://dx.doi.org/10.1016/j.msard.2022.103863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088160/
https://www.ncbi.nlm.nih.gov/pubmed/35667316
http://dx.doi.org/10.1016/j.msard.2022.103863

Ejemplares similares